A review of recent journal highlights

Clinical and Experimental Dermatology

Volumn 29, Issue 3, 2004, Pages 341-343

  Grattan, C E H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACRIVASTINE; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; AUTOANTIBODY; CELECOXIB; CETIRIZINE; CYCLOOXYGENASE 2 INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; ZAFIRLUKAST;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AUTOIMMUNITY; CLINICAL TRIAL; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SENSITIVITY; DRUG USE; ERYTHEMA; HUMAN; LABORATORY TEST; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE; SKIN MANIFESTATION; SKIN TEST; URTICARIA;

ASPIRIN; AUTOANTIBODIES; CYCLOOXYGENASE INHIBITORS; DRUG ERUPTIONS; HUMANS; LEUKOTRIENE ANTAGONISTS; SKIN TESTS; URTICARIA;

EID: 2442702984     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2004.01557.x     Document Type: Review

References (12)

1. Quiralte J, Saenz de San Pedro B, Florido JJ. Safety of selective cyclo-oxygenase-2 inhibitor rofecoxib in patients with NSAID-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002; 89: 63-6.
2. Pacor ML, Di Lorenzo G, Biasi D et al. Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or non-steroidal anti-inflammatory drugs. Clin Exp Allergy 2002; 32: 397-400.
3. Perrone MR, Artesani MC, Gaeta MV et al. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 2003; 132: 82-6.
4. Zembowicz A, Mastalerz L, Setkowicz M et al. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003; 139: 1577-82.
5. Pacor ML, Di Loranzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria and intolerance to food additives and/or acetylsalicylic acid. Clin Exp Allergy 2001; 31: 1607-14.
6. Reimers A, Pichler C, Helbling et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002; 32: 1763-8.
7. Zerbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002; 110: 484-8.
8. Asero R, Tedeschi A, Lorini M. Autoreactivity is highly prevalent in patients with multiple intolerances to NSAIDs. Ann Allergy Asthma Immunol 2002; 88: 468-72.
9. Asero R, Tedeschi A, Lorini M et al. Sera from patients with multiple drug allergy syndrome contain circulating histamine-releasing factors. Int Arch Allergy Immunol 2003; 131: 195-200.
10. Horn MP, Gerster T, Ochensberger B et al. Human anti-FcεRIα autoantibodies isolated from healthy donors cross-react with tetanus toxoid. Eur J Immunol 1999; 29: 1139-48.
11. Stadler B, Pachlopnik J, Vogel M et al. Conditional autoantibodies in urticaria patients: a unifying hypothesis. J Invest Dermatol Symp Proc 2001; 6: 150-2.
12. Pachlopnik JM, Horn MP, Fux M et al. Natural anti-FcεRIα autoantibodies may interfere with diagnostic tests for autoimmune urticaria. J Autoimmunity 2004; 22: 43-51.